FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s commercial product, AC5 ® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace,... Read More

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5 ® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando... Read More

FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5 ® Advanced Wound System (“AC5”). During its fourth... Read More

FRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5 ® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace, Las Vegas,... Read More

FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5 ® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure... Read More

FRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement with institutional and accredited individual investors (collectively, the “Investors”) as a Bridge Offering preceding a planned national exchange listing of the... Read More

FRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company will be exhibiting its AC5 ® Advanced Wound System (“ AC5 ”) at the Symposium on Advanced Wound Care (“ SAWC ”) Spring 2023, which takes place at National Harbor, MD from April 26-30,... Read More

FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“ CMS ”) Level II Healthcare Common Procedure Coding System (“ HCPCS ”) code dedicated to the Company’s AC5 ® Advanced Wound System (“ AC5 ”) went... Read More

FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“ CMS ”) established a new Level II Healthcare Common Procedure Coding System (“ HCPCS ”) code dedicated to the Company’s AC5 ® Advanced Wound System... Read More

FRAMINGHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced an expansion of its contracted sales force with a dedicated team of independent representatives whose primary objective will be to support surgeons and other medical professionals as well as advance the... Read More

FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “ Medical Advisory Board ”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric... Read More

FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it will effect a 1-for-200 reverse stock split of its outstanding and authorized common stock, effective at 5:00 p.m. (EST) on January 17, 2023. Arch’s common stock will continue to trade on the OTCQB... Read More